Edition:
United Kingdom

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Global Market

0.50USD
23 May 2018
Change (% chg)

$-0.01 (-1.86%)
Prev Close
$0.51
Open
$0.50
Day's High
$0.51
Day's Low
$0.48
Volume
52,645
Avg. Vol
131,543
52-wk High
$3.47
52-wk Low
$0.48

Select another date:

Tue, May 8 2018

BRIEF-Egalet Reports Q1 Loss Per Share $0.26

* EGALET CORP - NET PRODUCT SALES OF $6.3 MLN FOR QUARTER ENDED MARCH 31, 2018 COMPARED TO $5.4 MLN Source text for Eikon: Further company coverage:

BRIEF-Egalet Corp Says A National Pharmacy Benefit Manager Has Placed Sprix Nasal Spray In A Tier 2 Preferred Position

* EGALET CORP - A NATIONAL PHARMACY BENEFIT MANAGER HAS PLACED SPRIX NASAL SPRAY IN A TIER 2 PREFERRED POSITION EFFECTIVE IMMEDIATELY

BRIEF-Egalet Announces Two Large Regional Health Plans Placed Arymo® Er In Preferred Formulary Position

* EGALET ANNOUNCES TWO LARGE NORTHEAST REGIONAL HEALTH PLANS PLACED ARYMO® ER IN PREFERRED FORMULARY POSITION

BRIEF-Egalet Says Filed Patent Infringement Lawsuit Against Teva Pharmaceuticals USA

* EGALET SAYS ON APRIL 4 UNITS OF CO FILED A PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT AGAINST TEVA PHARMACEUTICALS USA, INC - SEC FILING

BRIEF-Egalet Reports Q4 Earnings Per Share $0.03

* EGALET REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Egalet Announces A Large Regional Health Plan

* EGALET ANNOUNCES A LARGE REGIONAL HEALTH PLAN PLACED ARYMO® ER AND SPRIX® NASAL SPRAY IN PREFERRED FORMULARY POSITIONS

BRIEF-Egalet Says Received Notice From Teva Pharmaceuticals USA Of ANDA Submission For Approval To Market Generic Version Of Arymo ER Extended-Release Tablets

* EGALET - CO, UNIT RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA OF ANDA SUBMISSION FOR APPROVAL TO MARKET GENERIC VERSION OF ARYMO ER EXTENDED-RELEASE TABLETS

BRIEF-Broadfin Capital Reports 9.99 Pct Passive Stake In Egalet Corp

* BROADFIN CAPITAL LLC REPORTS A 9.99 PCT PASSIVE STAKE IN EGALET CORP AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2lRMZcH) Further company coverage:

BRIEF-Egalet Partners With Orapharma To Co-Promote Sprix Nasal Spray

* EGALET PARTNERS WITH ORAPHARMA TO CO-PROMOTE SPRIX® NASAL SPRAY

BRIEF-Egalet Reduces Announces Refinancing Of Existing Convertible Notes

* EGALET REDUCES DEBT OBLIGATION, EXTENDS MATURITY AND LOWERS ANNUAL INTEREST PAYMENTS THROUGH REFINANCING OF EXISTING CONVERTIBLE NOTES

Select another date: